Evidence map›Paper›PMID 42230652›Full record

ArticleNPJ breast cancer2026

Machine learning-based identification of high-risk triple-negative breast cancer patients despite pathological complete response after neoadjuvant chemotherapy.

Koen Kwakkenbos, Nadine S van den Ende, Bernadette A M Heemskerk-Gerritsen, Jifke F Veenland, Agnes Jager, Carolien H M van Deurzen

Abstract read
In one paragraph

Article in NPJ breast cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Koen KwakkenbosDepartment of Pathology and Clinical Bioinformatics, Erasmus MC Cancer Institute, Erasmus University Medical Centre, Rotterdam, The Netherlands. k.kwakkenbos@erasmusmc.nl.
Nadine S van den EndeDepartment of Pathology and Clinical Bioinformatics, Erasmus MC Cancer Institute, Erasmus University Medical Centre, Rotterdam, The Netherlands.
Bernadette A M Heemskerk-GerritsenDepartment of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Centre, Rotterdam, The Netherlands.
Jifke F VeenlandDepartment of Radiology and Nuclear Medicine, Erasmus University Medical Centre, Rotterdam, The Netherlands.
Agnes Jager *Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Centre, Rotterdam, The Netherlands.
Carolien H M van Deurzen *Department of Pathology and Clinical Bioinformatics, Erasmus MC Cancer Institute, Erasmus University Medical Centre, Rotterdam, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The binary pathological complete response (pCR) status of triple-negative breast cancer (TNBC) patients after neoadjuvant chemotherapy (NAC) inadequately captures risk heterogeneity for prognosis. Therefore, this study aimed to develop a machine learning-based survival model to predict individualized overall survival (OS) in TNBC patients with pCR after NAC. This retrospective study utilized a Dutch nationwide cohort of TNBC patients, diagnosed between 2013 and 2021. We trained a survival model on the data using nested 5-fold cross-validation. Patients were stratified into a low- and high-risk group, based on the predicted survival probabilities. A total of 2642 patients with a pCR post-NAC were included, of whom 2620 were used in the final analysis. The survival model achieved good discrimination (C-index 0.754). Risk stratification identified a high-risk subgroup (n = 495, 18.9%) with significantly worse survival compared to the low-risk group (5-year OS 85.2% vs. 96.7%, log-rank P < 0.001). Pre-treatment nodal status (cN) was the strongest predictor, followed by age and clinical tumor stage (cT). This nationwide analysis demonstrates that TNBC patients achieving pCR remain a heterogeneous group with distinct survival outcomes. Machine learning-based survival modeling may enable individualized risk prediction using routinely collected clinical variables and may guide future post-surgical treatment escalation for high-risk TNBC patients despite pCR.

Identifiers

PMID42230652
PMCPMC13526796

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.